BioMarin Pharmaceutical 미래 성장
Future 기준 확인 3/6
BioMarin Pharmaceutical (는) 각각 연간 27.3% 및 7.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 26% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 11.9% 로 예상됩니다.
주요 정보
27.3%
수익 성장률
26.0%
EPS 성장률
| Biotechs 수익 성장 | 28.3% |
| 매출 성장률 | 7.7% |
| 향후 자기자본 수익률 | 11.9% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 18 Nov 2024 |
최근 미래 성장 업데이트
Recent updates
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar
Nov 14
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 3,403 | 792 | 962 | 937 | 23 |
| 12/31/2025 | 3,102 | 583 | 794 | 823 | 28 |
| 12/31/2024 | 2,815 | 398 | 657 | 607 | 29 |
| 9/30/2024 | 2,753 | 322 | 311 | 415 | N/A |
| 6/30/2024 | 2,588 | 257 | 223 | 329 | N/A |
| 3/31/2024 | 2,472 | 205 | 173 | 280 | N/A |
| 12/31/2023 | 2,419 | 168 | 52 | 159 | N/A |
| 9/30/2023 | 2,311 | 147 | 25 | 139 | N/A |
| 6/30/2023 | 2,235 | 100 | 34 | 161 | N/A |
| 3/31/2023 | 2,173 | 72 | 15 | 147 | N/A |
| 12/31/2022 | 2,096 | 142 | 148 | 176 | N/A |
| 9/30/2022 | 2,008 | 84 | 151 | 180 | N/A |
| 6/30/2022 | 1,912 | 54 | 106 | 119 | N/A |
| 3/31/2022 | 1,880 | 39 | 134 | 146 | N/A |
| 12/31/2021 | 1,846 | -64 | 185 | 305 | N/A |
| 9/30/2021 | 1,849 | 16 | 165 | 280 | N/A |
| 6/30/2021 | 1,917 | 837 | 155 | 269 | N/A |
| 3/31/2021 | 1,844 | 795 | 92 | 214 | N/A |
| 12/31/2020 | 1,860 | 854 | 15 | 85 | N/A |
| 9/30/2020 | 1,863 | 852 | 75 | 156 | N/A |
| 6/30/2020 | 1,847 | 122 | 58 | 140 | N/A |
| 3/31/2020 | 1,805 | 114 | 3 | 88 | N/A |
| 12/31/2019 | 1,704 | -24 | -90 | 48 | N/A |
| 9/30/2019 | 1,603 | -43 | -59 | 40 | N/A |
| 6/30/2019 | 1,533 | -110 | -112 | 17 | N/A |
| 3/31/2019 | 1,519 | -90 | -87 | 8 | N/A |
| 12/31/2018 | 1,491 | -77 | -74 | 20 | N/A |
| 9/30/2018 | 1,496 | -125 | -12 | -15 | N/A |
| 6/30/2018 | 1,439 | -125 | N/A | -23 | N/A |
| 3/31/2018 | 1,383 | -145 | N/A | 29 | N/A |
| 12/31/2017 | 1,314 | -117 | N/A | -9 | N/A |
| 9/30/2017 | 1,255 | -156 | N/A | -24 | N/A |
| 6/30/2017 | 1,201 | -181 | N/A | -72 | N/A |
| 3/31/2017 | 1,184 | -563 | N/A | -137 | N/A |
| 12/31/2016 | 1,117 | -630 | N/A | -228 | N/A |
| 9/30/2016 | 1,045 | -471 | N/A | -293 | N/A |
| 6/30/2016 | 974 | -524 | N/A | -286 | N/A |
| 3/31/2016 | 924 | -187 | N/A | -253 | N/A |
| 12/31/2015 | 890 | -172 | N/A | -219 | N/A |
| 9/30/2015 | 892 | -310 | N/A | -179 | N/A |
| 6/30/2015 | 859 | -212 | N/A | -185 | N/A |
| 3/31/2015 | 801 | -163 | N/A | -183 | N/A |
| 12/31/2014 | 749 | -134 | N/A | -70 | N/A |
| 9/30/2014 | 666 | -126 | N/A | -58 | N/A |
| 6/30/2014 | 627 | -187 | N/A | -59 | N/A |
| 3/31/2014 | 572 | -175 | N/A | -54 | N/A |
| 12/31/2013 | 548 | -176 | N/A | -57 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: BMRN 의 연간 예상 수익 증가율( 27.3% )이 saving rate( 2.6% 보다 높습니다. ).
수익 vs 시장: BMRN 의 연간 수익( 27.3% ) US 시장( 15.3% 보다 빠르게 성장할 것으로 예상됩니다. 15.3% 연간).
고성장 수익: BMRN 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.
수익 대 시장: BMRN 의 수익(연간 7.7% ) US 시장( 8.9% 보다 느리게 성장할 것으로 예상됩니다. 8.9% 연간).
고성장 수익: BMRN 의 수익(연간 7.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: BMRN 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 11.9 %).